Transformation from polycythemia vera to acute promyelocytic leukemia: Case report and literature review

Medicine (Baltimore). 2022 Aug 12;101(32):e30064. doi: 10.1097/MD.0000000000030064.

Abstract

Introduction: Transformation from chronic myeloproliferative neoplasm to acute leukemia is a feature of myeloproliferative neoplasm; however, the rate is not high. Transformation to acute promyelocytic leukemia is rare. Here, we report a case of transformation of polycythemia vera to acute promyelocytic leukemia and describe a process of clonal evolution that has not yet been reported.

Patient concerns: In this case, a 51-year-old woman was diagnosed with polycythemia vera and concomitant JAK2/V617F mutations in July 2019. She underwent intermittent phlebotomy and oral hydroxyurea irregularly. After 2 years, the patient complained of fatigue and poor sleep quality for 2 months.

Diagnosis: Further examination revealed marked hypercellularity and grade 1 bone marrow fibrosis with the PML/RARαV variant (23.85% mutation load), WT1-Exon1 (37.8%), WT1-Exon9 (4.1%), JAK3-Exon7 (49.3%), and RELN-Exon55 (45.8%). According to the World Health Organization classification of tumors of hematopoietic and lymphoid tissues, the patient was ultimately diagnosed with a rare transformation of polycythemia vera to acute promyelocytic leukemia.

Interventions: The patient underwent dual induction therapy with all-trans-retinoic acid and arsenic trioxide.

Outcomes: After 28 days of induction therapy, the patient achieved complete remission, was compliant and the treatment was well tolerated.

Conclusion: Polycythemia vera can transform into acute promyelocytic leukemia; therefore, it is important to review bone aspiration and other tests to perform a comprehensive assessment and monitor the disease status, to detect disease progression and intervene early when it transforms into acute promyelocytic leukemia.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Arsenic Trioxide
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute* / diagnosis
  • Leukemia, Promyelocytic, Acute* / drug therapy
  • Leukemia, Promyelocytic, Acute* / genetics
  • Middle Aged
  • Myeloproliferative Disorders* / complications
  • Polycythemia Vera* / complications
  • Polycythemia Vera* / diagnosis
  • Polycythemia Vera* / genetics
  • Primary Myelofibrosis* / complications

Substances

  • Arsenic Trioxide